CIBMTR Real-World Outcomes of Frail Patients Treated with Idecabtagene Vicleucel (IMS 2026) - Sep 11, 2026 - Abstract #PA-077; Pres time: Sep 25, 2026; "With extended follow-up, ide-cel demonstrated comparable effectiveness and broadly similar safety, except for higher ICANS, in frail and non-frail pts, supporting its use across a wide RRMM population."
Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Multiple Myeloma • Respiratory Diseases
|
|
Omar Nadeem1; Othman S. Akhtar2; Ajay K. Nooka3; Surbhi Sidana4; Krina Patel5; Marcelo C. Pasquini2; Sophie Hello6; Maryna Levikova6; Romain Piault6; Devender S. Dhanda6; Doris Hansen7
|